Lilly ungguli Novo di pasar GLP-1 oral (LLY:NYSE)
· seekingalpha.com
Terapi GLP-1 oral milik Eli Lilly (LLY), Foundayo, melampaui estimasi penjualan kuartal kedua 2026, memanaskan persaingan dengan pil Wegovy milik Novo (NVO). Baca selengkapnya di sini.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...